APLT — Applied Therapeutics Inc

Applied Therapeutics Inc (APLT) is a biotechnology company listed on NASDAQ. It is led by Les D. Funtleyder, based in 545 Fifth Avenue, New York, NY, United States, 10017, with about 28 employees. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.

Latest reported APLT revenue for 2025-09-30 was $1.0M. Net income was -$62.1M. APLT currently screens at market cap $14.9M.

Use this APLT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the APLT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the APLT SEC filings page. Lician reads the product cache first so this HTML stays unique to Applied Therapeutics Inc even when a live quote feed is slow.